NASDAQ: BLLN
Billiontoone Inc Stock

$103.76+1.54 (+1.51%)
Updated Nov 11, 2025
BLLN Price
$103.76
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$93.50
52 Week High
$113.06
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.57
Operating Cash Flow
N/A
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BLLN Overview

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BLLN's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
B
BLLN
Ranked
#25 of 46

Top Ranked Stocks in Industry

View Top Diagnostic & Research Stocks

Be the first to know about important BLLN news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLLN's short-term assets ($236.15M) exceed its short-term liabilities ($39.87M)
Short-term Liabilities Financials
BLLN's short-term assets ($236.15M) exceed its long-term liabilities ($103.60M)
Long-term Liabilities Financials
BLLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more BLLN due diligence checks available for Premium users.

Valuation

BLLN's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%

Assets to liabilities

Assets
$312.6M
Liabilities
$143.5M
Debt to equity
-0.57
BLLN's short-term assets ($236.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLLN's short-term assets ($236.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

BLLN vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BNRB$128.57M-2.05%-6.30x1.64x
BIAFF$2.05M+3.35%-0.10x-0.96x
CDNAB$863.04M+0.48%14.34x2.77x
CAIB$7.10B+1.45%N/A14.84x
BLLNCN/A+1.51%N/AN/A

Billiontoone Stock FAQ

What is Billiontoone's quote symbol?

(NASDAQ: BLLN) Billiontoone trades on the NASDAQ under the ticker symbol BLLN. Billiontoone stock quotes can also be displayed as NASDAQ: BLLN.

If you're new to stock investing, here's how to buy Billiontoone stock.

What is the 52 week high and low for Billiontoone (NASDAQ: BLLN)?

(NASDAQ: BLLN) Billiontoone's 52-week high was $113.06, and its 52-week low was $93.50. It is currently -8.23% from its 52-week high and 10.97% from its 52-week low.

How much is Billiontoone's stock price per share?

(NASDAQ: BLLN) Billiontoone stock price per share is $103.76 today (as of Nov 11, 2025).
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.